{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Life Science Solutions","title":"De-Risking Early-Stage Formulation Development: Inside the Kymanox Lab","html":"","width":"100%","height":180,"duration":1817,"description":"Every formulation decision made early in development carries downstream implications for stability, manufacturing, scalability, and analytical strategy. As therapies become more complex and development timelines compress, getting formulation right from the start has never mattered more.\nIn this episode of Life Science Solutions, host Chris Adkins sits down with Kymanox experts Ryan Doxey, VP of Technical Services, and Matt Owen, PhD Associate Director of CMC and Pharmaceutical Sciences. Together, they introduce the newly announced Kymanox Formulation Lab and discuss why having dedicated wet lab space is essential for true IND-enabling formulation development.\nWhile Contract Development and Manufacturing Organizations (CDMOs) are built for throughput and execution, they are typically not staffed or equipped to troubleshoot complex scientific issues. This episode explores how applying a \"science driving success\" approach early on bridges that gap and ensures that your clinical manufacturing timelines stay on track.\nTopics Include:The CDMO Bottleneck: Why contract manufacturers lack the agility to spend adequate time developing formulations, and how unsolved early issues cause costly delays in Phase 1 and Phase 2 clinical manufacturing.Quality by Design (QbD): Why developing a product merely to meet a Certificate of Analysis (CFA) is insufficient, and the importance of truly understanding your design space to inherently ensure a quality product.Real-World Case Studies: How unknown peaks during forced degradation/leachable studies can derail timelines, and why understanding complex interactions like heat-catalyzed oxidation is crucial before scaling up.Advanced Characterization: Why CDMOs often skip critical tests like permeation and mucus adhesion studies, and how using tools like nasal cast models ensures an intranasal product has adequate residence time and efficacy.Future Trends: The push for biologics and the resurgence of spray-dried formulations to improve...","thumbnail_url":"https://img.transistorcdn.com/NJUQJpllzMReojwXSp4vxSqDlm-PIulGozVxmRVQnJE/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8yOGM2/NjIwZTU1YjljMDM5/ZGRhMWZhODQ2OTAx/NjliZS5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}